348 related articles for article (PubMed ID: 32368176)
1. Immune checkpoint inhibitors in genitourinary malignancies.
Thana M; Wood L
Curr Oncol; 2020 Apr; 27(Suppl 2):S69-S77. PubMed ID: 32368176
[TBL] [Abstract][Full Text] [Related]
2. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
3. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.
Ornstein MC; Calabrese C; Wood LS; Kirchner E; Profusek P; Allman KD; Martin A; Kontzias A; Grivas P; Garcia JA; Calabrese LH; Rini BI
Clin Genitourin Cancer; 2019 Jun; 17(3):177-182. PubMed ID: 30824360
[TBL] [Abstract][Full Text] [Related]
4. Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy.
Bergerot CD; Bergerot PG; Philip EJ; Hsu JA; Dizman N; Vaishampayan U; Dorff T; Pal SK
J Immunother Cancer; 2019 Mar; 7(1):71. PubMed ID: 30867071
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy advances in uro-genital malignancies.
Ratta R; Zappasodi R; Raggi D; Grassi P; Verzoni E; Necchi A; Di Nicola M; Salvioni R; de Braud F; Procopio G
Crit Rev Oncol Hematol; 2016 Sep; 105():52-64. PubMed ID: 27372200
[TBL] [Abstract][Full Text] [Related]
6. Novel immunotherapy combinations for genitourinary cancers.
Al Harthy M; Redman J; Madan RA
Expert Opin Biol Ther; 2020 Mar; 20(3):253-262. PubMed ID: 31914333
[TBL] [Abstract][Full Text] [Related]
7. Current Landscape of Immunotherapy in Genitourinary Malignancies.
Alhalabi O; Rafei H; Bilen MA; Shah AY
Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
[TBL] [Abstract][Full Text] [Related]
8. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Siddiqui BA; Gheeya JS; Goswamy R; Bathala TK; Surasi DS; Gao J; Shah A; Campbell MT; Msaouel P; Goswami S; Wang J; Zurita AJ; Jonasch E; Corn PG; Aparicio AM; Siefker-Radtke AO; Sharma P; Subudhi SK; Tannir N
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326169
[TBL] [Abstract][Full Text] [Related]
9. From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer.
Tambaro R; Napoli MD; Pisano C; Cecere SC; Attademo L; Rossetti S; Feroce F; Setola S; Califano D; Russo D; Spina A; Perdonà S; Izzo A; Pignata S
Immunotherapy; 2021 Jan; 13(1):67-77. PubMed ID: 33045887
[TBL] [Abstract][Full Text] [Related]
10. Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers.
Karim F; Amin A; Liu M; Vishnuvardhan N; Amin S; Shabbir R; Swed B; Khan U
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627127
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer.
Gust KM; Rebhan K; Resch I; Shariat SF; Necchi A
Curr Opin Urol; 2020 Jul; 30(4):547-556. PubMed ID: 32453001
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapeutic agents for genitourinary cancers.
Zarrabi K; Paroya A; Wu S
J Hematol Oncol; 2019 Sep; 12(1):89. PubMed ID: 31484560
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.
Marciscano AE; Madan RA
Curr Treat Options Oncol; 2018 Mar; 19(3):16. PubMed ID: 29520448
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers.
Labadie BW; Balar AV; Luke JJ
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771578
[TBL] [Abstract][Full Text] [Related]
15. Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies.
Solanki AA; Bossi A; Efstathiou JA; Lock D; Mondini M; Ramapriyan R; Welsh J; Kang J
Eur Urol Oncol; 2019 Feb; 2(1):79-87. PubMed ID: 30929848
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.
Nathan P; Rajeh A; Noor M; Boldt G; Fernandes R
Curr Oncol; 2024 Apr; 31(4):2316-2327. PubMed ID: 38668075
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.
Lu K; Chiu KY; Cheng CL
Cancer Treat Res; 2022; 183():201-223. PubMed ID: 35551661
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies.
Jang A; Lanka SM; Jaeger EB; Lieberman A; Huang M; Sartor AO; Mendiratta P; Brown JR; Garcia JA; Farmer T; Sudhaman S; Mahmood T; Pajak N; Calhoun M; Dutta P; ElNaggar A; Liu MC; Barata PC
JCO Precis Oncol; 2023 Jul; 7():e2300131. PubMed ID: 37467457
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of avelumab for the treatment of genitourinary tumors.
Stühler V; Maas JM; Walz S; Stenzl A; Bedke J
Expert Opin Biol Ther; 2020 Sep; 20(9):971-979. PubMed ID: 32407144
[TBL] [Abstract][Full Text] [Related]
20. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
